Table 1.
Characteristics of cT2 N0 Patients by Treatment Modality (N = 69)
| Variablesa | Operation Only | Induction Therapy + Operation |
p Value |
|---|---|---|---|
| Patients | 14 (20.3) | 55 (79.7) | |
| Age at diagnosis, years | 69 (66–75) | 61 (53–66) | 0.014 |
| Sex | 0.980 | ||
| Male | 12 (85.7) | 47 (85.5) | |
| Female | 2 (14.3) | 8 (14.5) | |
| Race | 0.429 | ||
| White | 13 (92.9) | 49 (89.1) | |
| Black | 0 (0.0) | 4 (73) | |
| Other | 1 (7.1) | 2 (3.6) | |
| Smoked cigarettes | 0.734 | ||
| Never | 4 (28.5) | 13 (23.6) | |
| Ever | 10 (71.4) | 42 (76.4) | |
| Pack-years smoked | 40 (30–55) | 35 (20–50) | 0.727 |
| Histology | 0.030 | ||
| Adenocarcinoma | 14 (100) | 40 (72.7) | |
| Squamous cell | 0 (0.0) | 15 (27.3) | |
| Diagnostic Imaging | 0.025 | ||
| Computed tomography only | 1 (7.1) | 23 (41.8) | |
| Endoscopic ultrasound | 13 (92.9) | 32 (58.2) | |
| Neoadjuvant chemotherapy | |||
| 5-FU and platinum only | … | 37 (67.3) | |
| Non-5-FU and platinum | … | 12 (21.8) | |
| Unknown | … | 6 (10.9) | |
| Neoadjuvant radiotherapy dose |
|||
| <4,400 cGy | … | 4 (7.3) | |
| $ 4,400 cGy | … | 46 (83.6) | |
| Dose unknown | … | 5 (9.1) | |
| Surgical procedure | >0.99 | ||
| Transhiatal esophagectomy | 11 (78.6) | 39 (70.9) | |
| 3-Incision esophagectomy | 2 (14.3) | 7 (12.7) | |
| Ivor Lewis | 0 (0.0) | 3 (5.5) | |
| Esophagogastrectomy | 1 (7.1) | 6 (10.9) | |
| ASA classification | 0.762 | ||
| 1 | 0 (0.0) | 0 (0.0) | |
| 2 | 3 (21.4) | 9 (16.4) | |
| 3 | 11 (78.6) | 45 (81.8) | |
| 4 | 0 (0.0) | 1 (1.8) | |
| 5 | 0 (0.0) | 0 (0.0) | |
| Margin | 0.127 | ||
| R0 | 10 (71.4) | 50 (90.9) | |
| R1 | 3 (21.4) | 4 (7.3) | |
| Unknown | 1 (7.1) | 1 (1.8) | |
| Adjuvant chemotherapy | 0.865 | ||
| Received | 4 (28.6) | 17 (30.9) | |
| Did not receive | 10 (71.4) | 38 (69.1) | |
| Recurrent disease | 0.133 | ||
| Recurrence | 3 (21.4) | 21 (38.2) | |
| No recurrence | 11 (78.6) | 34 (61.8) | |
| Date of surgery, year | 2003 (2001–2004) | 1996 (1992–2002) | 0.001 |
| Time in days between | |||
| Diagnosis and operation | 28.5 (21–41) | 111 (93–129) | <0.001 |
| Diagnosis and treatment | 28.5 (21–41) | 32 (21–51) | 0.310 |
| Postop hospital LOS, days | 11 (9–18) | 10 (8–12) | 0.103 |
| Pathologic stage (T N M) | |||
| T0 N0 | 0 (0) | 22 (40) | |
| T1 N0 | 3 (21.4) | 6 (10.9) | |
| T2 N0 | 4 (28.6) | 5 (9.1) | |
| T3 N0 | 1 (7.1) | 5 (9.1) | |
| T1 N1 | 1 (7.1) | 2 (3.6) | |
| T2 N1 | 3 (21.4) | 10 (18.2) | |
| T3 N1 | 2 (14.3) | 5 (9.1) | |
| Pathologic stage (grouped) | |||
| <pT2 N0 | 3 (21.4) | 28 (50.9) | |
| >pT2 N0 | 11 (78.6) | 27 (49.1) |
a
Categoric data are presented as number (%); continuous data as median (interquartile range).
ASA = American Society of Anesthesiologists; LOS = length of stay; Postop = postoperative; T N M = tumor size, lymph nodes, metastasis.